Clinical determinants of a positive visual inspection after treatment with acetic acid for cervical cancer screening

Objective To examine the determinants of a positive visual inspection after acetic acid (VIA), including the relationship of testing positive for high‐risk human papillomavirus (HR‐HPV), which is the necessary cause of cervical cancer. Design A prospective cohort study. Setting Three clinical sites...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:BJOG : an international journal of obstetrics and gynaecology 2014-05, Vol.121 (6), p.739-746
Hauptverfasser: Castle, PE, Qiao, Y‐L, Zhao, F‐H, Chen, W, Valdez, M, Zhang, X, Kang, L‐N, Bansil, P, Paul, P, Bai, P, Peck, R, Li, J, Chen, F, Jeronimo, J
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Objective To examine the determinants of a positive visual inspection after acetic acid (VIA), including the relationship of testing positive for high‐risk human papillomavirus (HR‐HPV), which is the necessary cause of cervical cancer. Design A prospective cohort study. Setting Three clinical sites in rural China. Population A total of 7541 women aged 25–65 years. Methods All women underwent VIA, DNA testing, by two DNA tests performed on both clinician‐ and self‐collected specimens, and HPV E6 oncoprotein testing. Those positive by any test underwent colposcopy and four‐quadrant biopsy evaluation. A random sample of women with negative screening results also underwent colposcopy and, if colposcopic abnormalities were observed, four‐quadrant biopsy evaluation was performed. Women diagnosed with cervical intraepithelial neoplasia grade 2 (CIN2), or more severe grades (CIN2 + ), underwent treatment. Main outcome measure Testing positive for VIA. Results Overall, 7.6% (95% confidence interval, 95% CI, 7.0–8.2%) had a positive VIA. Women who tested positive for HPV were more likely to have a positive VIA than women who tested negative for HPV (15.0%, 95% CI 12.9–17.2% versus 6.3%, 95% CI 5.7–6.9%; P 
ISSN:1470-0328
1471-0528
DOI:10.1111/1471-0528.12646